WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that the Company's Quell®
Wearable Pain Relief Technology™ has won the Electronics Retailer
Association Moxie
Award for the Best Health Show 2016. This Moxie award recognizes the
year's best direct response television campaigns.
"We are proud that Quell advertising was recognized with the prestigious
Moxie award," said Frank McGillin, Senior Vice President and General
Manager, Consumer. "Quell is a breakthrough for the 100 million
Americans suffering from chronic pain, and we are pleased that our
television campaign is effectively communicating our message."
About Quell Wearable Pain Relief Technology
Quell is FDA cleared and designed for the millions of people suffering
from chronic pain. The advanced wearable technology delivers 100% drug
free pain relief and is available without a prescription. Quell can be
used during the day while active, and at night while sleeping. Quell
gives users the option to start, stop, and adjust therapy discreetly via
their smartphone. It also provides therapy utilization and advanced
sleep tracking. Quell is available at select healthcare professionals
and retailers. To find a Quell retailer, visit the Store
Locator at QuellRelief.com.
About the Electronic Retailing Association
The Electronic Retailing Association (ERA) serves as the exclusive trade
association representing the $350 billion direct-to-consumer
marketplace. ERA membership spans the globe to encompass all levels of
direct marketers, from start-up companies to global leaders that employ
the power of direct response to market across all platforms including
television, digital media and radio to achieve a consumer-direct,
measurable and accountable response. ERA can be visited on the Internet
at www.retailing.org.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders and diabetes. The
company's lead product is Quell®, an over-the-counter
wearable therapeutic device for chronic pain. Quell is integrated into a
digital health platform that helps patients optimize their therapy and
decrease the impact of chronic pain on their quality of life. The
company also markets DPNCheck®, a rapid point-of-care test
for diabetic neuropathy, which is the most common long-term complication
of Type 2 diabetes. The company maintains an active research effort and
has several pipeline programs, including a therapeutic device for
restless leg syndrome. The company is located in Waltham,
Massachusetts and was founded as a spinoff from the Harvard-MIT Division
of Health Sciences and Technology in 1996. For more information, please
visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160916005685/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
